<DOC>
	<DOC>NCT00334295</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.</brief_summary>
	<brief_title>Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Histologically confirmed, recurrent or metastatic endometrial carcinoma Postmenopausal Hormonreceptor positive Pretreatment with Fulvestrant Previous endocrine therapy of the endometrial carcinoma Previous malignancy less than 3 years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Recurrent or metastatic endometrial carcinoma</keyword>
</DOC>